News
HAE
84.70
+0.73%
0.61
Is Haemonetics Corporation's (NYSE:HAE) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Haemonetics (NYSE:HAE) has a return on equity of 13% and a decent earnings growth rate of 14%. We look at the company's ROE to compare it to its industry average. Haemonetics has a respectable 13% return on Equity. The company has grown its net income growth over the last five years. The stock is up 9.2% for the last month. Haemonetic is reinvesting heavily into its business.
Simply Wall St · 3d ago
Weekly Report: what happened at HAE last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at HAE last week (0311-0315)?
Weekly Report · 03/18 09:02
Haemonetics (HAE) Recently Broke Out Above the 50-Day Moving Average
NASDAQ · 03/11 13:30
Weekly Report: what happened at HAE last week (0304-0308)?
Weekly Report · 03/11 09:02
Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Haemonetics Corporation's (NYSE:HAE) estimated fair value is US$120 based on 2 Stage Free Cash Flow to Equity. Haemonetics' US$77.45 share price signals that it might be 35% undervalued. We will use a discounted cash flow model to estimate the company's intrinsic value. The company is valued at 35% below its current share price.
Simply Wall St · 03/07 12:19
Haemonetics Corporation: Improved Performance, Another Bolt-On Deal
Haemonetics Corporation has announced a deal to acquire Attune Medical in a $160 million cash deal. Haemonetics has seen improvements in its business after a tough period during the pandemic. The company's share price has lagged, but the company's adjusted earnings multiples have fallen below 20 times. The blood player announced another bolt-on acquisition in March 2024.
Seeking Alpha · 03/06 22:38
Haemonetics (HAE) Signs Agreement to Acquire Attune Medical
NASDAQ · 03/06 11:54
BUZZ-U.S. STOCKS ON THE MOVE-Nasdaq, Albemarle, Haemonetics
Dow Jones Industrial Average was down 0.72% at 38,708.35. Top three S&P 500 percentage gainers: Target, DaVita, Haemonetics. Apple and Tesla weighed on the Nasdaq. Apple down 2.7% as sales of iPhones fall in China.
Reuters · 03/05 19:01
BUZZ-Haemonetics rises on deal to acquire medical device maker Attune Medical
Shares of healthcare company Haemonetics rise 1.8% to $76.13. Co announces definitive agreement to acquire medical device maker Attune Medical. HAE to gain access to Attune's esophageal cooling device, ensoETM, as part of the deal.
Reuters · 03/05 17:50
Needham Remains a Hold on Haemonetics (HAE)
TipRanks · 03/05 17:15
Haemonetics to Buy Attune Medical for $160 Million >HAE
Boston medical-technology company Haemonetics to buy Attune Medical for $160 million in cash. The company will buy the maker of the ensoETM cooling device. The device is the only FDA-approved cooling device for esophageal procedures. Haemonetic expects to complete the acquisition in the first quarter of 2025.
Dow Jones · 03/05 11:40
Haemonetics to buy Attune Medical for $160M
Healthcare M&A Haemonetics to buy Attune Medical for $160M. Attune medical is the manufacturer of the ensoETM. Proactive esophageal cooling device. The company expects the acquisition to be immediately accretive to revenue and earnings growth.
Seeking Alpha · 03/05 11:37
*Haemonetics Plans to Finance This Acquisition Through a Combination of Cash-On-Hand and a Draw Under Its Revolving Credit Facility >HAE
Dow Jones · 03/05 11:01
Press Release: Haemonetics Announces Definitive Agreement to Acquire Attune Medical
Haemonetics Announces Definitive Agreement to Acquire Attune Medical. The ensoETM is the only FDA-cleared temperature regulation device indicated for esophageal protection during radiofrequency cardiac ablation procedures. Haemonetics will pay $160 million for the manufacturer of the device. The company expects the acquisition to be completed in the first quarter of 2024.
Dow Jones · 03/05 11:00
*Haemonetics Acquisition Is Expected to Be Completed in 1Q of Haemonetics' Fiscal Yr 2025 >HAE
Dow Jones · 03/05 11:00
*Haemonetics Announces Definitive Agreement To Acquire Attune Medical >HAE
Dow Jones · 03/05 11:00
*Haemonetics Will Acquire Attune Medical for an Upfront Cash Payment of $160 M at Closing Plus Additional Contingent Consideration >HAE
Dow Jones · 03/05 11:00
Weekly Report: what happened at HAE last week (0226-0301)?
Weekly Report · 03/04 09:02
What Makes Haemonetics (HAE) a New Buy Stock
NASDAQ · 02/27 17:00
More
Webull provides a variety of real-time HAE stock news. You can receive the latest news about Haemonetics Corp Mass through multiple platforms. This information may help you make smarter investment decisions.
About HAE
Haemonetics Corporation is a global healthcare company. The Company provides a suite of medical products and solutions for customers to help them improve patient care and reduce the cost of healthcare. Its technology addresses three medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. Its segments include Plasma, Blood Center, and Hospital. Its Plasma segment offers automated plasma collection systems, donor management software, and supporting software solutions that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to collect and separate blood components for transfusions. Its Hospital segment provides patient care and has four product lines: hemostasis management, vascular closure, cell salvage, and transfusion management. Its portfolio also includes fiber optic sensor technology in the interventional cardiology market.